PTC Therapeutics (PTCT) closed at $60.23 on November 18, 2026, down 0.2% from the previous close, on volume of 589,008 shares (30-day average 1,016,987).
Data as of November 18, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Calendar Put Ratio Spread | 15-Jan-27 70[383x]|21-Jan-28 70[348x] P | 731 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
PTC Therapeutics Earnings Call Highlights Sephience Growth
TipRanks (Sat, 14-Nov 7:17 PM ET)
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
PRNewswire (Tue, 3-Nov 7:00 AM ET)
PTC Therapeutics to Participate in Upcoming Investor Conferences
PRNewswire (Mon, 2-Nov 8:00 AM ET)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 30-Oct 4:30 PM ET)
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PRNewswire (Thu, 29-Oct 4:02 PM ET)
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
PRNewswire (Thu, 15-Oct 8:01 AM ET)
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
PRNewswire (Mon, 21-Sep 4:30 PM ET)
PRNewswire (Mon, 24-Aug 8:00 AM ET)
Market Chameleon (Fri, 8-May 7:21 AM ET)
PTC Therapeutics Grants Stock Options and RSUs to New Hires Under Nasdaq Rule 5635(c)(4)
Market Chameleon (Mon, 16-Mar 4:42 AM ET)
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
PTC Therapeutics trades on the NASDAQ stock market under the symbol PTCT.
As of November 18, 2026, PTCT stock price declined to $60.23 with 589,008 million shares trading.
PTCT has a beta of 0.88, meaning it tends to be less sensitive to market movements. PTCT has a correlation of 0.08 to the broad based SPY ETF.
PTCT has a market cap of $5.03 billion. This is considered a Mid Cap stock.
Last quarter PTC Therapeutics reported $358 million in Revenue and $.94 earnings per share. This beat revenue expectation by $52 million and exceeded earnings estimates by $.67.
In the last 3 years, PTCT traded as high as $90.87 and as low as $20.50.
The top ETF exchange traded funds that PTCT belongs to (by Net Assets): IJR, VTI, XBI, IWM, VB.
PTCT has underperformed the market in the last year with a price return of -20.3% while the SPY ETF gained +10.8%. PTCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.4% and -11.6%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
PTCT support price is $58.60 and resistance is $62.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTCT shares will trade within this expected range on the day.